Business
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization
RepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization.
About this update from Replicel Life Sciences Inc.
[{"type":"text","content":"\n\n\n\nRepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nRepliCel Pursues Non-Diluting Grant Funding to Accelerate Value Creation and Commercialization\nPR Newswire\nVANCOUVER, March 7, 2017\n\n\n\nVANCOUVER, March 7, 2017 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) (\"RepliCel\" or the \"Company\"), a clinical stage regenerative medicine company developing unique biologic products for pattern baldness and thinning hair, aging and sun-damaged skin, and chronic tendon degeneration, today announced the company has retained The FreeMind Group (\"FreeMind\"), a premier international firm that assists life science organizations in securing non-dilutive funding from granting agencies and private foundations. RepliCel aims to secure non-dilutive capital to support research, clinical development, and/or manufacturing priorities to accelerate value creation and the commercialization of its products.\n\n\"We have a number of strategic clinical and non-clinical projects which are ideally positioned for external collaborations and non-dilutive funding. These include basic research, manufacturing optimization, product development, and clinical objectives which have the potential to create significant intellectual property and shareholder value,\" stated RepliCel President and CEO, R. Lee Buckler. \"FreeMind has a proven track record and commitment to success-based remuneration that convinces us they will bring significant value to our programs. I look forward to updating our shareholders over the coming months with their progress.\"\n\nAbout The FreeMind GroupEstablished in 1999, The FreeMind Group is the largest consulting group of its kind working with academics and industry alike. Their goal is to assist in maximizing potential to receive funding from non-dilutive sources. They have experience in seeking funding from nearly all NIH Institutes, Department of Defense, NSF, FDA, BARDA, etc., as well as private foundations. FreeMind's team is dedica...